Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Recruiting now · Phase 3
Conditions studied: Cutaneous Squamous Cell Carcinoma (CSCC)
In brief
This study will test a study drug called cemiplimab to see if it can help treat early-stage Cutaneous Squamous Cell Carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called Programmed cell Death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. The study is looking at: * The side effects cemiplimab might cause * How well cemiplimab works compared to surgery
Key facts
- Study ID
- NCT06585410
- Run by
- Regeneron Pharmaceuticals
- People needed
- 369
- Starts
- 2025-01-02
- Expected to finish
- 2030-05-03
- Last updated by the study team
- 2026-07-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of New Mexico — Albuquerque, New Mexico, United States (enrolling)
- Medical Dermatology Specialists - Phoenix — Phoenix, Arizona, United States (enrolling)
- Mayo Clinic - Arizona — Scottsdale, Arizona, United States (enrolling)
- UC San Diego Moores Cancer Center — La Jolla, California, United States (enrolling)
- Profound Research, Dermatology Medical Group - Oceanside — Oceanside, California, United States (enrolling)
- University of Arizona Cancer Center — Tucson, Arizona, United States (enrolling)
- Arkansas Research Trials — North Little Rock, Arkansas, United States (enrolling)
- George Washington University Medical Faculty Associates — Washington D.C., District of Columbia, United States (enrolling)
- Life Clinical Trials — Coral Springs, Florida, United States (enrolling)
- Dermatology Associates of the Palm Beaches, Integri Research at Dermatology Associates — Delray Beach, Florida, United States (enrolling)
- University of South Florida — Tampa, Florida, United States (enrolling)
- University of Chicago Medical Center — Chicago, Illinois, United States (enrolling)
- Oak Dermatology — Naperville, Illinois, United States (enrolling)
- Stanford University — Redwood City, California, United States (enrolling)
- Peak Dermatology, Aesthetics and Wellness — Visalia, California, United States (enrolling)
- US Dermatology Partners DBA DermAssociates, PC — Rockville, Maryland, United States (enrolling)
- Northeast Dermatology Associates — Beverly, Massachusetts, United States (enrolling)
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- MyMichigan Dermatologic Oncology — Midland, Michigan, United States (enrolling)
- Somerset Skin Centre — Troy, Michigan, United States (enrolling)
- Dermatology and Skin Cancer Center — Lee's Summit, Missouri, United States (enrolling)
- Washington University in St. Louis - Center for Dermatologic and Cosmetic Surgery — St Louis, Missouri, United States (enrolling)
- Las Vegas Dermatology — Las Vegas, Nevada, United States (enrolling)
- StracSkin, PLLC — Portsmouth, New Hampshire, United States (enrolling)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.